Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Policy & Legislation » Cures Act Gives Precision Medicine Proponents, Diagnostics Companies Reasons to Celebrate

Cures Act Gives Precision Medicine Proponents, Diagnostics Companies Reasons to Celebrate

Dec 29, 2016
|
Turna Ray
Premium

NEW YORK (GenomeWeb) – The passage of the 21st Century Cures Act at the tail end of 2016 gave precision medicine proponents and diagnostics developers reason for optimism, though detractors fear the bill gives industry players too much leeway in the name of innovation and at a cost to public health protections.  

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

UK Funds Challenge Trial

The UK is investing £33.6 million into a controversial human SARS-CoV-2 challenge study, according to Reuters.

Watching the Changes

The Guardian reports that the UK COVID genomics consortium is monitoring mutations that are arising within circulating SARS-CoV-2 strains for any that may affect future vaccines.

Max Planck, Nature Strike a Deal

Science reports that Max Planck and Nature have struck a deal for affiliated authors to publish papers that are accessible to the public as well as access Nature-branded journals.

PNAS Papers on Ancient Tibetan Animals, HNSCC Drug Response, More

In PNAS this week: genomic analysis of ancient animals from Tibet, oncoproteins tied to WEE1 kinase enzyme inhibitor response, and more.

Oct
22
Featured Webinar

Adoption of Broad NGS Profiling for HRR Deficiency: Looking Beyond BRCA, SNPs, and Indels

Sponsored by
Sophia Genetics

This webinar will share the Lorraine Cancer Institute's experience in implementing a novel targeted solution to accurately assess homologous recombination repair (HRR) deficiency by analyzing a series of genes, beyond BRCA, and calling multiple types of variants, including copy number variants (CNVs).

Oct
28
Featured Webinar

How Low Can You Go? Reduce Breeding Costs with an Optimized Genotyping and Analysis Strategy

Sponsored by
NRGene

Molecular breeding methods such as genomic selection and genome-wide association studies often require high-density genotypic data from many samples, but the cost and complexity of genotyping at this scale may be prohibitive.

Oct
29
Featured Webinar

How to Train Your DRAGEN for Pathology Informatics

Sponsored by
Illumina

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.

Nov
03
Featured Webinar

A Streamlined Targeted NGS Workflow for Comprehensive Genomic Profiling of Different Tumor Samples

Sponsored by
Agilent

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

What's Popular?

In Molecular Diagnostics

  1. Centogene Increases Full-Year Revenue Guidance; CEO Resigns

  2. CMS Colon Cancer Screening Memo Bodes Well for Assays in Development; Denies Epi ProColon

  3. Interdisciplinary NIST Team Claims qPCR Improvements Using Unusual Math Tweaks

    Premium

  4. FDA Reissues Emergency Use Authorization for Thermo Fisher Scientific COVID-19 Combo Kit

  5. LumiraDx Gets FDA Emergency Use Authorization for PCR-Based Coronavirus Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.